<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1338325</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Bibliometric and visualization analyses of cancer-related fatigue research published worldwide from 2001 to 2023</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Peijin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2102594"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2378085"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Feng</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1695355"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ding</surname>
<given-names>Zhiguo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fan</surname>
<given-names>Weijing</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2523886"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Traditional Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy for Medical Sciences and Peking Union Medical College</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Oncology, Dongzhimen Hospital of Beijing University of Chinese Medicine</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Thyropathy, Sunsimiao Hospital of Beijing University of Chinese Medicine, Tongchuan</institution>, <addr-line>Shanxi</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Thyropathy, Dongzhimen Hospital of Beijing University of Chinese Medicine</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Vascular Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Radhika Gangaraju, University of Alabama at Birmingham, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Mellar Pilgrim Davis, Geisinger Health System, United States</p>
<p>Semra Bulbuloglu, Istanbul Ayd&#x131;n University, T&#xfc;rkiye</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Li Feng, <email xlink:href="mailto:fengli663@126.com">fengli663@126.com</email>; Zhiguo Ding, <email xlink:href="mailto:dingzhiguo_1@163.com">dingzhiguo_1@163.com</email>; Weijing Fan, <email xlink:href="mailto:fan18811023202@126.com">fan18811023202@126.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1338325</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>11</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Li, Wang, Feng, Ding and Fan</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Li, Wang, Feng, Ding and Fan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>Cancer seriously endangers human health and represents a global public health issue. Cancer-related fatigue (CRF) is a distressing and persistent sense of exhaustion caused by cancer or cancer treatment, widely prevalent among cancer patients. This study aims to summarize emerging trends and provide directions for future research of CRF through bibliometric and visualization analyses.</p>
</sec>
<sec>
<title>Methods</title>
<p>A systematic search in the Web of Science Core Collection database from 2001-01-01 to 2023-05-18 were conducted. Only reviews and articles written in English were considered. CiteSpace and the R were used for bibliometric and visualization analyses.</p>
</sec>
<sec>
<title>Results</title>
<p>The analysis revealed that 2,566 studies on CRF have been published by 1,041 institutions in 70 countries so far. The number of articles published and cited annually have been steadily increasing. Eduardo Bruera published the most articles, and Julienne E Bower is the most co-cited author. The University of Texas System is the leading institution in cancer-related fatigue research. The United States and China have the largest number of publications. Supportive Care in Cancer published the most articles, and Journal of Clinical Oncology is the most co-cited journal. &#x201c;Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis&#x201d;, authored by Mustian KM et&#xa0;al. and published in JAMA Oncology was the most co-cited document. Keyword analysis indicated that research focus had shifted from &#x201c;epoetin alpha&#x201d; and &#x201c;anemia&#x201d; to &#x201c;risk factors&#x201d;, &#x201c;systematic review&#x201d;, &#x201c;acupuncture&#x201d;, &#x201c;anxiety&#x201d;, &#x201c;traditional Chinese medicine&#x201d; and &#x201c;guidelines&#x201d;.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>In conclusion, this analysis provides comprehensive research trends and knowledge network maps of CRF. Clinical physicians should concurrently focus on the anemia, insomnia, anxiety, and depression status of patients when assessing or managing CRF. Improvements in related risk factors also contribute to alleviating fatigue. Furthermore, it is essential to pay attention to authoritative CRF guidelines. Acupuncture and traditional Chinese medicine also have therapeutic potential, which merits further investigation. Researchers should draw attention to the crucial roles of inflammation, hypoxia, and mitochondrial dysfunction, which could be the frontiers.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cancer-related fatigue</kwd>
<kwd>bibliometric analysis</kwd>
<kwd>CiteSpace</kwd>
<kwd>inflammation</kwd>
<kwd>hypoxia</kwd>
<kwd>exercise</kwd>
</kwd-group>
<counts>
<fig-count count="11"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="115"/>
<page-count count="17"/>
<word-count count="7238"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Epidemiology and Prevention</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Cancer-related fatigue (CRF) is a subjective feeling of tiredness or exhaustion associated with cancer or cancer treatment, encompassing physical, emotional, and/or cognitive aspects (<xref ref-type="bibr" rid="B1">1</xref>). In a meta-analysis of 144,813 participants conducted in 2020, the estimated diagnostic yield for CRF was 52% (<xref ref-type="bibr" rid="B2">2</xref>). Up to 80% of patients treated with chemotherapy and/or radiotherapy experience CRF (<xref ref-type="bibr" rid="B3">3</xref>). Chemotherapy and radiotherapy are the main factors that contribute to CRF. Other therapeutic modalities, such as targeted therapy, immunotherapy, and surgical treatments, o cancer itself, are also associated with CRF.</p>
<p>Cancer survivors may experience fatigue for months, years, or even up to a decade (<xref ref-type="bibr" rid="B4">4</xref>). CRF is more distressing and long-lasting than general fatigue and cannot be alleviated by resting. It often causes patients with cancer unbearable suffering, severely affects quality of life, disrupts daily functioning, interferes with subsequent therapies, and influences prognosis. Therefore, alleviating CRF is crucial for improving the overall quality of life of patients with cancer.</p>
<p>Since the 20th century, many studies have revealed the occurrence of fatigue symptom in cancer patients. Consequently, studies have been conducted to elucidate the assessment, treatment, and possible mechanisms of CRF, providing new perspectives and hotspots in the field of cancer research. Nevertheless, effective measures for reducing CRF are still limited, which are primarily non-pharmacological treatments, such as exercise and yoga. This is partly due to the obscure mechanisms underlying the occurrence of CRF. Currently, the proposed possible hypotheses for CRF include the dysregulation of inflammatory cytokines and dysfunction of skeletal muscles and mitochondria. It is important for physicians and researchers to understand the progression and characteristics of research related to CRF, which can facilitate the identification of future research directions and more efficient approaches to treating CRF.</p>
<p>Bibliometric analysis is an emerging analytical technique that is used to summarize advances in a certain field, reveal research hotspots, and quantitatively outline the contributions of authors, journals, institutions, and countries (<xref ref-type="bibr" rid="B5">5</xref>). However, no bibliometric or visualization analyses of studies on CRF have been conducted to date. CiteSpace (<xref ref-type="bibr" rid="B6">6</xref>) is a bibliometric tool that is commonly used to visualize information extracted from articles. The aim of this study was to conduct bibliometric and visualization analyses of CRF research published in the Web of Science Core Collection (WoSCC) database from 2001 to 2023, to summarize emerging trends and provide directions for future research.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Search strategy and data acquisition</title>
<p>Two investigators (PJL and QW) conducted a systematic search in the WoSCC database, covering the period from January 1st, 2001 to May 18th, 2023. In cases of disagreement, a third reviewer (ZGD) provided the final decision. The search queries used were TS = (cancer-related fatigue), and the publication date range was set from 2001-01-01 to 2023-05-18. The search was limited to the Social Sciences Citation Index (SSCI) and Science Citation Index Expanded (SCI-EXPANDED) editions. Only reviews and articles written in English were considered, while other article types such as conference abstracts and editorials were excluded. This study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (<xref ref-type="bibr" rid="B7">7</xref>) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;1</bold>
</xref>). The systematic search yielded 3,154 records, and 2,566 studies were included in the final analysis (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). All relevant publications were downloaded on May 18th, 2023. The results were stored in download_results.txt format, and the content included &#x201c;full record and cited references.&#x201d;</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flowchart of the retrieval process.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Data analysis</title>
<p>All data were imported into CiteSpace 6.2.R3 and duplicate entries were eliminated. The publication year was analyzed using WoSCC. The collaboration among authors, institutions, and countries, as well as the co-citation of references and journals, and the co-occurrence of keywords were visualized. The R package &#x201c;bibliometrix&#x201d; (<xref ref-type="bibr" rid="B8">8</xref>) was employed to analyze the geographical distribution of countries. The findings were presented in figures and tables using techniques such as time slicing, thresholding, and pruning. We set the time span as 2001.01&#x2013;2023.12 and the years per slice as 1, and chose the suitable pruning methods (minimum spanning tree, pathfinder, or no) according to the analysis results. The size of nodes in the various network maps was indicative of the frequency of co-occurrence or co-citation, while the color denoted the year. The citation bursts of references and keywords were analyzed to find the emerging themes in the CRF field. In the journal co-citation analysis, we merged the same journals (&#x201c;cancer&#x201d; and &#x201c;cancer-am cancer soc&#x201d;) to an alias list. The synonyms in keyword analysis were also merged, including &#x201c;cancer-related fatigue&#x201d; and &#x201c;cancer related fatigue,&#x201d; &#x201c;cancer survivors&#x201d; and &#x201c;survivors,&#x201d; etc.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Annual distribution of publications</title>
<p>2566 articles and review articles pertaining to CRF were published from January 2001 to May 2023. As depicted in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>, there has been a stable growth trend in the number of annual publications and citations since 2001, as heightened interests among scholars in this domain. Notably, the most number of publications reached 271 in 2021 and 2022, and the highest increasing number reached 82 from 2019 to 2020. The citations ranged from 69 in 2002 to a substantial 11,731 in 2022, reflecting increasing attention to the CRF field.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Annual distribution of publications. The bar graph represents the number of publications and the line graph represents the number of citations.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Analysis of co-authorship and co-cited authors</title>
<p>A total of 10,649 authors published studies about CRF according to CiteSpace. Eduardo Bruera published the most articles (n = 35), followed by Christine Miaskowski (n = 30), Leorey N Saligan (n = 29), Sriram Yennurajalingam (n = 25), and Julienne E Bower (n = 23) (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). However, the density of author collaboration was relatively low, reflecting that scholars need to enhance further cooperation in this field. The network map outlines the potential collaboration among authors, including 10,170 connections (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Some authors have exhibited close collaborative relationships, such as Julienne E Bower and Patricia A Ganz. The degree of centrality can help us identify hubs in the map, and Paul B Jacobsen has the highest centrality (= 0.04), showing a lack of close cooperation.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>The top 10 authors and co-cited authors in CRF research.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Rank</th>
<th valign="top" align="center">Author</th>
<th valign="top" align="center">Count (%)</th>
<th valign="top" align="center">Centrality</th>
<th valign="top" align="center">Co-cited author</th>
<th valign="top" align="center">Co-citation (%)</th>
<th valign="top" align="center">Centrality</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">1</td>
<td valign="top" align="center">Eduardo Bruera</td>
<td valign="top" align="center">35 (0.24%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Julienne E Bower</td>
<td valign="top" align="center">897 (3.20%)</td>
<td valign="top" align="center">0.16</td>
</tr>
<tr>
<td valign="top" align="center">2</td>
<td valign="top" align="center">Christine Miaskowski</td>
<td valign="top" align="center">30 (0.20%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Ann M Berger</td>
<td valign="top" align="center">582 (2.07%)</td>
<td valign="top" align="center">0.13</td>
</tr>
<tr>
<td valign="top" align="center">3</td>
<td valign="top" align="center">Leorey N Saligan</td>
<td valign="top" align="center">2 (0.20%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">David Cella</td>
<td valign="top" align="center">520 (1.85%)</td>
<td valign="top" align="center">0.13</td>
</tr>
<tr>
<td valign="top" align="center">4</td>
<td valign="top" align="center">Sriram Yennurajalingam</td>
<td valign="top" align="center">25 (0.17%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Ollie Minton</td>
<td valign="top" align="center">360 (1.39%)</td>
<td valign="top" align="center">0.03</td>
</tr>
<tr>
<td valign="top" align="center">5</td>
<td valign="top" align="center">Julienne E Bower</td>
<td valign="top" align="center">23 (0.16%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">G A Curt</td>
<td valign="top" align="center">355 (1.28%)</td>
<td valign="top" align="center">0.11</td>
</tr>
<tr>
<td valign="top" align="center">6</td>
<td valign="top" align="center">Karen M Mustian</td>
<td valign="top" align="center">22 (0.15%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Victoria Mock</td>
<td valign="top" align="center">312 (1.27%)</td>
<td valign="top" align="center">0.04</td>
</tr>
<tr>
<td valign="top" align="center">7</td>
<td valign="top" align="center">Steven M Paul</td>
<td valign="top" align="center">21 (0.14%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Tito R Mendoza</td>
<td valign="top" align="center">300 (1.11%)</td>
<td valign="top" align="center">0.05</td>
</tr>
<tr>
<td valign="top" align="center">8</td>
<td valign="top" align="center">Jon D Levine</td>
<td valign="top" align="center">21 (0.14%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Paul B Jacobsen</td>
<td valign="top" align="center">281 (1.07%)</td>
<td valign="top" align="center">0.08</td>
</tr>
<tr>
<td valign="top" align="center">9</td>
<td valign="top" align="center">Patricia A Ganz</td>
<td valign="top" align="center">20 (0.14%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Wang XS</td>
<td valign="top" align="center">277 (1.00%)</td>
<td valign="top" align="center">0.04</td>
</tr>
<tr>
<td valign="top" align="center">10</td>
<td valign="top" align="center">Hans Knoop</td>
<td valign="top" align="center">20 (0.14%)</td>
<td valign="top" align="center">0.03</td>
<td valign="top" align="center">Patrick Stone</td>
<td valign="top" align="center">275 (0.99%)</td>
<td valign="top" align="center">0.06</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>
<bold>(A)</bold> The network of co-authorship. <bold>(B)</bold> The network of co-cited authors. Each node and the size of it represent an author/co-cited author and his number of studies/co-citations. Each line represents author collaboration. The different colors indicate the different years of publications. The purple nodes represent that the centrality of co-cited authors is &gt; 0.10.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g003.tif"/>
</fig>
<p>A co-citation relationship was established among the authors when they were cited simultaneously in one or more articles. The core authors can be shown intuitively through the network map (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). CiteSpace identified 1,007 co-cited authors, with 25 of them being co-cited over 200 times and 66 being co-cited no less than 100 times. The most co-cited authors were Julienne E Bower (897 co-citations), Ann M Berger (582 co-citations), David Cella (520 co-citations), Ollie Minton (360 co-citations), and G A Curt (355 co-citations) (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>).</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Analysis of co-institution and co-country</title>
<p>From 2001 to the present, 1,041 institutions from 70 countries had published studies about CRF. The top 5 productive institutions were the University of Texas System (178, 2.77%), UTMD Anderson Cancer Center (159, 2.48%), University of California System (141, 2.19%), Research Libraries UK (131, 2.04%), and Harvard University (84, 1.31%), four of which were from the USA (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Research Libraries UK exhibited the highest centrality (= 0.36). As can be seen from the pruning network map of co-institution (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>), the collaboration among some institutions is relatively close, such as Anderson Cancer Center and University of Texas System, as well as Research Libraries UK and Harvard University.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>The top 10 institutions and countries in CRF research.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Rank</th>
<th valign="top" align="center">Institution</th>
<th valign="top" align="center">N (%)</th>
<th valign="top" align="center">Centrality</th>
<th valign="top" align="center">Country</th>
<th valign="top" align="center">N (%)</th>
<th valign="top" align="center">Centrality</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">1</td>
<td valign="top" align="center">University of Texas System</td>
<td valign="top" align="center">178 (2.77%)</td>
<td valign="top" align="center">0.07</td>
<td valign="top" align="center">USA</td>
<td valign="top" align="center">1065 (31.26%)</td>
<td valign="top" align="center">0.50</td>
</tr>
<tr>
<td valign="top" align="center">2</td>
<td valign="top" align="center">UTMD Anderson Cancer Center</td>
<td valign="top" align="center">159 (2.48%)</td>
<td valign="top" align="center">0.05</td>
<td valign="top" align="center">China</td>
<td valign="top" align="center">314 (9.22%)</td>
<td valign="top" align="center">0.05</td>
</tr>
<tr>
<td valign="top" align="center">3</td>
<td valign="top" align="center">University of California System</td>
<td valign="top" align="center">141 (2.19%)</td>
<td valign="top" align="center">0.21</td>
<td valign="top" align="center">Germany</td>
<td valign="top" align="center">206 (6.05%)</td>
<td valign="top" align="center">0.25</td>
</tr>
<tr>
<td valign="top" align="center">4</td>
<td valign="top" align="center">Research Libraries UK</td>
<td valign="top" align="center">131 (2.04%)</td>
<td valign="top" align="center">0.36</td>
<td valign="top" align="center">England</td>
<td valign="top" align="center">193 (5.66%)</td>
<td valign="top" align="center">0.20</td>
</tr>
<tr>
<td valign="top" align="center">5</td>
<td valign="top" align="center">Harvard University</td>
<td valign="top" align="center">84 (1.31%)</td>
<td valign="top" align="center">0.18</td>
<td valign="top" align="center">Canada</td>
<td valign="top" align="center">186 (5.46%)</td>
<td valign="top" align="center">0.05</td>
</tr>
<tr>
<td valign="top" align="center">6</td>
<td valign="top" align="center">National Institutes of Health-USA</td>
<td valign="top" align="center">82 (1.28%)</td>
<td valign="top" align="center">0.11</td>
<td valign="top" align="center">Australia</td>
<td valign="top" align="center">179 (5.25%)</td>
<td valign="top" align="center">0.12</td>
</tr>
<tr>
<td valign="top" align="center">7</td>
<td valign="top" align="center">Pennsylvania Commonwealth System of Higher Education</td>
<td valign="top" align="center">59<break/>(0.92%)</td>
<td valign="top" align="center">0.05</td>
<td valign="top" align="center">Netherlands</td>
<td valign="top" align="center">151 (4.43%)</td>
<td valign="top" align="center">0.12</td>
</tr>
<tr>
<td valign="top" align="center">8</td>
<td valign="top" align="center">University of California Los Angeles</td>
<td valign="top" align="center">57 (0.89%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Italy</td>
<td valign="top" align="center">95 (2.79%)</td>
<td valign="top" align="center">0.06</td>
</tr>
<tr>
<td valign="top" align="center">9</td>
<td valign="top" align="center">University of Toronto</td>
<td valign="top" align="center">56 (0.87%)</td>
<td valign="top" align="center">0.09</td>
<td valign="top" align="center">Spain</td>
<td valign="top" align="center">82 (2.41%)</td>
<td valign="top" align="center">0.04</td>
</tr>
<tr>
<td valign="top" align="center">10</td>
<td valign="top" align="center">University of London</td>
<td valign="top" align="center">55 (0.86%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">France</td>
<td valign="top" align="center">73 (2.14%)</td>
<td valign="top" align="center">0.03</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>
<bold>(A)</bold> The network of co-institutions. <bold>(B)</bold> The network of co-countries. Each node and the size of it represent an institution/country and its number of publications. The thickness of each line represents the strength of collaboration. The different colors indicate the different years of publications. The purple nodes represent that the centrality of co-cited authors is &gt; 0.10.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g004.tif"/>
</fig>
<p>The United States (1065, 31.26%) had the largest number of publications on CRF, followed by China (314, 9.22%), Germany (206, 6.05%), England (193, 5.66%), and Canada (186, 5.46%) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;2</bold>
</xref>). 70 nodes and 471 connections made up the network map of countries co-occurrence with a density of 0.195 (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). The USA serves as a pivotal intermediary in the CRF area, exemplifying substantial contributions to the CRF area and assuming the central roles. <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref> visually represents the global distribution of publications, highlighting the cooperation among countries.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The geographical distribution of global publications.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g005.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Analysis of journals and co-cited journals</title>
<p>650 journals were identified through WoSCC. Supportive Care in Cancer published the most studies (212, 8.26%), followed by Journal of Pain and Symptom Management (116, 4.52%), Cancer (71, 2.77%), Cancer Nursing (62, 2.42%), and Integrative cancer therapies (58, 2.26%) (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>). Of the top 10 journals publishing the most articles in the CRF field, Cancer had the highest impact factor (IF) of 6.16, while no journals with an IF &gt; 10 were observed.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>The top 10 journals in CRF research.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Rank</th>
<th valign="top" align="center">Journal</th>
<th valign="top" align="center">N (%)</th>
<th valign="top" align="center">IF (2022)</th>
<th valign="top" align="center">Quartile (2022)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">1</td>
<td valign="top" align="center">Supportive Care in Cancer</td>
<td valign="top" align="center">212 (8.26%)</td>
<td valign="top" align="center">3.13</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">2</td>
<td valign="top" align="center">Journal of Pain and Symptom Management</td>
<td valign="top" align="center">116 (4.52%)</td>
<td valign="top" align="center">4.70</td>
<td valign="top" align="center">Q1</td>
</tr>
<tr>
<td valign="top" align="center">3</td>
<td valign="top" align="center">Cancer</td>
<td valign="top" align="center">71 (2.77%)</td>
<td valign="top" align="center">6.16</td>
<td valign="top" align="center">Q1</td>
</tr>
<tr>
<td valign="top" align="center">4</td>
<td valign="top" align="center">Cancer Nursing</td>
<td valign="top" align="center">62 (2.42%)</td>
<td valign="top" align="center">2.59</td>
<td valign="top" align="center">Q1</td>
</tr>
<tr>
<td valign="top" align="center">5</td>
<td valign="top" align="center">Integrative cancer therapies</td>
<td valign="top" align="center">58 (2.26%)</td>
<td valign="top" align="center">2.95</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">6</td>
<td valign="top" align="center">Psycho-oncology</td>
<td valign="top" align="center">58 (2.26%)</td>
<td valign="top" align="center">3.55</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">7</td>
<td valign="top" align="center">BMC Cancer</td>
<td valign="top" align="center">44 (1.72%)</td>
<td valign="top" align="center">3.77</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">8</td>
<td valign="top" align="center">Cancers</td>
<td valign="top" align="center">41 (1.59%)</td>
<td valign="top" align="center">5.21</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">9</td>
<td valign="top" align="center">European Journal of Cancer Care</td>
<td valign="top" align="center">39 (1.52%)</td>
<td valign="top" align="center">2.07</td>
<td valign="top" align="center">Q2</td>
</tr>
<tr>
<td valign="top" align="center">10</td>
<td valign="top" align="center">Oncology Nursing Forum</td>
<td valign="top" align="center">36 (1.40%)</td>
<td valign="top" align="center">1.86</td>
<td valign="top" align="center">Q3</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>We analyzed the co-cited journals with k = 5 from time slicing of 1 year, and 286 co-cited journals were identified. The co-citations of six journals were more than 1,000, and 20 journals were more than 500. The most co-cited journals were the Journal of Clinical Oncology (1900, 4.41%), Cancer (1806, 4.19%), Supportive Care in Cancer (1674, 3.89%), Journal of Pain and Symptom Management (1562, 3.63%), Annals of Oncology (1080, 2.51%), and Oncology Nursing Forum (1025, 2.38%) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;2</bold>
</xref>). Of these, Annals of Oncology had the highest IF (= 50.45), followed by the Journal of Clinical Oncology (IF = 45.27). 286 nodes and 2,324 connections made up the network map of countries co-occurrence with a density of 0.057 (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>). Supportive Care in Cancer had the highest centrality (= 0.11), followed by PLOS ONE (= 0.09), Psycho-oncology (= 0.07), Medicine &amp; Science in Sports &amp; Exercise (= 0.07), and Integrative cancer therapies (= 0.07).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>The network of co-cited journals. Each node and the size of it represent a co-cited journal and its number of co-citations. The thickness of each line represents the strength of collaboration. The different colors indicate the different years of publications.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g006.tif"/>
</fig>
<p>The dual-map overlay of the journals revealed the relationship distribution of subject categories among the journals (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). Three predominant citation paths colored with green were identified, which means that the studies published in the Medicine/Medical/Clinical journals were mainly cited by those published in the Molecular/Biology/Genetics (z = 4.39, f = 11,470), Health/Nursing/Medicine (z = 7.10, f = 18,100), and Psychology/Education/Social journals (z = 2.43, f = 6,698).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>The dual-map overlay of journals. The citing journals were on the left of the map, and the cited ones were on the right. The length of the ellipse represents the number of authors, and the width indicates the count of publications.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g007.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Analysis of co-cited reference</title>
<p>When the documents were cited simultaneously, a co-citation relationship was established among them. We analyzed the most co-cited references (k = 25) with a time slicing of 1 year. The core references can be displayed visually through the network map (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref>), containing 6,980 links with a density of 0.0076. Of 1,360 co-cited references identified through CiteSpace, 13 were co-cited no less than 50 times, and 117 were co-cited no less than 20 times. <xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref> displays the top 10 co-cited references. &#x201c;Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis&#x201d;, authored by Mustian KM et&#xa0;al. and published in JAMA Oncology was the most co-cited document in the CRF area, which indicated that exercise and psychological treatments were more effective than pharmaceutical interventions for CRF through meta-analyses (<xref ref-type="bibr" rid="B9">9</xref>). Berger AM et&#xa0;al. provided recommendations for screening and treatments of CRF (<xref ref-type="bibr" rid="B10">10</xref>). Bower JE et&#xa0;al. summarized the possible mechanisms, risk factors, and treatments for CRF (<xref ref-type="bibr" rid="B4">4</xref>). Campbell KL et&#xa0;al. provided a consensus statement about exercise recommendations for cancer survivors (<xref ref-type="bibr" rid="B11">11</xref>). Hilfiker R et&#xa0;al. (<xref ref-type="bibr" rid="B12">12</xref>) evaluated the effects of non-pharmaceutical interventions on CRF. Overall, 6 of the top 10 most co-cited documents were reviews, and 4 were guidelines.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>The network of co-cited references. Each node and the size of it represent a co-cited reference and its number of co-citations. The different colors indicate the different years of publications.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g008.tif"/>
</fig>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>The top 10 co-cited references in CRF research.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Rank</th>
<th valign="top" align="center">Author</th>
<th valign="top" align="center">Cited reference</th>
<th valign="top" align="center">Co-citation (%)</th>
<th valign="top" align="center">Centrality</th>
<th valign="top" align="center">Journal</th>
<th valign="top" align="center">IF (2021)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">1</td>
<td valign="top" align="center">Mustian KM (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td valign="top" align="center">Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis</td>
<td valign="top" align="center">133 (1.26%)</td>
<td valign="top" align="center">0.16</td>
<td valign="top" align="center">JAMA Oncology</td>
<td valign="top" align="center">28.37</td>
</tr>
<tr>
<td valign="top" align="center">2</td>
<td valign="top" align="center">Berger AM (<xref ref-type="bibr" rid="B10">10</xref>)</td>
<td valign="top" align="center">Cancer-Related Fatigue, Version 2.2015</td>
<td valign="top" align="center">103 (0.98%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Journal of the National Comprehensive Cancer Network</td>
<td valign="top" align="center">13.44</td>
</tr>
<tr>
<td valign="top" align="center">3</td>
<td valign="top" align="center">Bower JE (<xref ref-type="bibr" rid="B4">4</xref>)</td>
<td valign="top" align="center">Cancer-related fatigue&#x2013;mechanisms, risk factors, and treatments</td>
<td valign="top" align="center">99 (0.94%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Nature Reviews Clinical Oncology</td>
<td valign="top" align="center">78.77</td>
</tr>
<tr>
<td valign="top" align="center">4</td>
<td valign="top" align="center">Campbell KL (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td valign="top" align="center">Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable</td>
<td valign="top" align="center">62 (0.59%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Medicine &amp; Science in Sports &amp; Exercise</td>
<td valign="top" align="center">4.15</td>
</tr>
<tr>
<td valign="top" align="center">5</td>
<td valign="top" align="center">Hilfiker R (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td valign="top" align="center">Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis</td>
<td valign="top" align="center">61 (0.58%)</td>
<td valign="top" align="center">0.05</td>
<td valign="top" align="center">British Journal of Sports Medicine</td>
<td valign="top" align="center">18.42</td>
</tr>
<tr>
<td valign="top" align="center">6</td>
<td valign="top" align="center">Bower JE (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td valign="top" align="center">Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation</td>
<td valign="top" align="center">61 (0.58%)</td>
<td valign="top" align="center">0.06</td>
<td valign="top" align="center">Journal of Clinical Oncology</td>
<td valign="top" align="center">45.27</td>
</tr>
<tr>
<td valign="top" align="center">7</td>
<td valign="top" align="center">Abrahams HJG (<xref ref-type="bibr" rid="B14">14</xref>)</td>
<td valign="top" align="center">Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors</td>
<td valign="top" align="center">54 (0.51%)</td>
<td valign="top" align="center">0.09</td>
<td valign="top" align="center">Annals of Oncology</td>
<td valign="top" align="center">50.45</td>
</tr>
<tr>
<td valign="top" align="center">8</td>
<td valign="top" align="center">Fabi A (<xref ref-type="bibr" rid="B15">15</xref>)</td>
<td valign="top" align="center">Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment</td>
<td valign="top" align="center">53 (0.50%)</td>
<td valign="top" align="center">0.01</td>
<td valign="top" align="center">Annals of Oncology</td>
<td valign="top" align="center">50.45</td>
</tr>
<tr>
<td valign="top" align="center">9</td>
<td valign="top" align="center">Hofman M (<xref ref-type="bibr" rid="B16">16</xref>)</td>
<td valign="top" align="center">Cancer-related fatigue: the scale of the problem</td>
<td valign="top" align="center">53 (0.50%)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">Oncologist</td>
<td valign="top" align="center">5.76</td>
</tr>
<tr>
<td valign="top" align="center">10</td>
<td valign="top" align="center">Saligan LN (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td valign="top" align="center">The biology of cancer-related fatigue: a review of the literature</td>
<td valign="top" align="center">52 (0.49%)</td>
<td valign="top" align="center">0.04</td>
<td valign="top" align="center">Supportive Care in Cancer</td>
<td valign="top" align="center">3.13</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>
<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9</bold>
</xref> displays the top 25 documents with the strongest citation bursts, showing growing interest in the emerging field. The earliest beginning year of citation burst of reference was from 2002 to 2005 (strength = 19.63), entitled &#x201c;Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition&#x201d; (<xref ref-type="bibr" rid="B18">18</xref>) by Curt GA et&#xa0;al. and published in Oncologist. &#x201c;Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis&#x201d; (<xref ref-type="bibr" rid="B9">9</xref>) published by Mustian KM et&#xa0;al. had the strongest strength of 50.32, which was also the most co-cited reference.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>The top 25 references with strongest citation bursts. Red lines represent the duration of citation bursts. The figure was arranged in descending order based on the strength of citation bursts.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g009.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Analysis of keyword</title>
<p>Keywords represent a high generalization of the central theme of an article. Analyzing keywords can help to identify the research hot spots in the CRF field over a period of time. We analyzed the top 50 highest-frequency keywords in each time slice. 565 nodes and 4,178 connections made up the network map of keywords co-occurrence with a density of 0.0262 (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>). Of 565 keywords identified through CiteSpace, 31 appeared over 100 times, and 111 appeared no less than 10 times. <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;3</bold>
</xref> presents the top 20 keywords in CRF research. The main contents of the CRF field were identified as &#x201c;Quality of life&#x201d; (1315), &#x201c;breast cancer&#x201d; (841), &#x201c;survivors&#x201d; (614), &#x201c;management&#x201d; (564), &#x201c;chemotherapy&#x201d; (471), &#x201c;physical activity&#x201d; (370), and &#x201c;depression&#x201d; (355). 10 clusters were revealed in the cluster analysis of keywords through CiteSpace (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>), including survivorship, assessment, yoga, proinflammatory cytokines, validation, cognitive impairment, inflammation, anemia, exercise, hypoxia, and chemotherapy.</p>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>The network of the top 50 keywords co-occurrence and the cluster analysis. Each node and the size of it represent a co-cited reference and its number of co-citations. The different colors indicate the different years of publications. The phrases in # represent the clusters of keywords.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g010.tif"/>
</fig>
<p>
<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11</bold>
</xref> displays the top 50 keywords with the strongest citation bursts, which elucidates the evolving patterns of focal points in the CRF area. Notably, the keyword &#x201c;epoetin alpha&#x201d; was the strongest burst (strength = 26.78) and also has the earliest year of citation bursts (2001). The keywords &#x201c;risk factors,&#x201d; &#x201c;systematic review,&#x201d; &#x201c;acupuncture,&#x201d; &#x201c;anxiety,&#x201d; and &#x201c;traditional Chinese medicine&#x201d; appeared in 2019, while &#x201c;guidelines&#x201d; occurred in 2021, which were the most recent citation bursts. Moreover, &#x201c;insomnia,&#x201d; &#x201c;colorectal cancer,&#x201d; &#x201c;risk factors,&#x201d; &#x201c;systematic review,&#x201d; and &#x201c;guidelines&#x201d; have continued to be of ongoing interest until the year 2023.</p>
<fig id="f11" position="float">
<label>Figure&#xa0;11</label>
<caption>
<p>The top 50 keywords with strongest citation bursts. Red lines represent the duration of citation bursts. The figure was arranged in ascending order based on the beginning year of burst.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1338325-g011.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<sec id="s4_1">
<label>4.1</label>
<title>Summary of findings</title>
<p>This study conducted bibliometric and visualization analyses using CiteSpace to examine 2,566 scientific articles published between 2001 and 2023, providing comprehensive knowledge network maps of CRF. The findings indicate that CRF has garnered extensive attention since 2001, with a notable surge in interest observed in 2019, showing sustained attention towards CRF over the coming years. The most prolific author is Eduardo Bruera from the UTMD Anderson Cancer Center, and the most co-cited author is Julienne E Bower from the University of California. Additionally, the University of Texas System is the most productive institution. Nine countries (the USA, Germany, England, Canada, Netherlands, Italy, France, Japan, and Greece) have embarked on comprehensive research on CRF since 2001. Here in this article the United States and China made the most contributions to this field. However, the low centrality of China highlights the need for Chinese scholars to enhance international association and collaboration.</p>
<p>Supportive Care in Cancer published the most studies on CRF, while Journal of Clinical Oncology has the highest number of co-citations. Most-cited references generally address the possible mechanisms and treatments of CRF. The top ten keywords with the highest frequency of occurrence are quality of life, cancer-related fatigue, breast cancer, survivors, management, chemotherapy, randomized controlled trial, fatigue, physical activity, and depression. Our analysis of keywords with the strongest citation bursts have revealed that &#x201c;yoga,&#x201d; &#x201c;inflammation,&#x201d; &#x201c;hypoxia,&#x201d; &#x201c;anemia,&#x201d; &#x201c;exercise,&#x201d; &#x201c;acupuncture,&#x201d; &#x201c;anxiety,&#x201d; &#x201c;traditional Chinese medicine,&#x201d; and &#x201c;insomnia&#x201d; might be emerging hotspots in the CRF area.</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Research hotspots on CRF</title>
<p>We summarized the hotspots in CRF research based on the results obtained from CiteSpace, primarily encompassing risk factors (anemia, insomnia, depression, and anxiety), treatments (exercise, yoga, acupuncture, and traditional Chinese medicine), and mechanisms (inflammation and hypoxia) of CRF.</p>
<sec id="s4_2_1">
<label>4.2.1</label>
<title>Risk factors</title>
<p>Previous reports have indicated that several factors, including anemia, insomnia, anxiety, and depression, are essential for the occurrence and development of fatigue in patients with cancer (<xref ref-type="bibr" rid="B19">19</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>Patients with cancer often have anemia, especially during or after chemotherapy. Low hemoglobin levels often cause a decrease in blood oxygen levels, leading to the development of some fatigue-related symptoms. These findings have prompted attempts to investigate the correlations between cancer-related anemia and CRF. Some evidence shows that administration of epoetin or darbepoetin to increase hemoglobin level is an effective therapy for reducing CRF (<xref ref-type="bibr" rid="B19">19</xref>). However, this treatment may be limited to patients with cancer-related anemia caused by hematological malignancies, such as lymphoma or multiple myeloma, or cancer treatments, such as chemotherapy (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). The analysis conducted in the present study revealed that the keywords &#x201c;epoetin alpha&#x201d; and &#x201c;anemia&#x201d; have the earliest year of citation bursts (2001); however, this surge only lasted until 2012, indicating that the effect of anemia on CRF has not been a topic of interest in recent years.</p>
<p>Approximately 25-59% of patients with cancer experience insomnia. Insomnia is a prevalent type of sleep disorder characterized by poor sleep quality and difficulties with sleep initiation and maintenance (<xref ref-type="bibr" rid="B24">24</xref>). The National Comprehensive Cancer Network (NCCN) has identified that insomnia has a critical influence on CRF (<xref ref-type="bibr" rid="B1">1</xref>). A meta-analysis of 144,813 patients with cancer indicated that insomnia has a significant effect on CRF (OR = 2.83), and that improved insomnia is associated with decreased levels of CRF (<xref ref-type="bibr" rid="B2">2</xref>). Several possible mechanisms, such as alterations in the circadian rhythm, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, inflammatory and immune responses, and abnormal neurotransmitter levels, may be implicated in the correlation between insomnia and CRF (<xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Anxiety and depression are common mental health problems that affect approximately 10-20% of patients with cancer. The correlation between CRF and anxiety/depression is undeniable. However, the association between CRF and depression seems to receive more attention than that between CRF and anxiety (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>). A systematic review of 59 studies showed that the correlation between anxiety (0.46) and CRF is weaker than that between depression and CRF (0.56) (<xref ref-type="bibr" rid="B29">29</xref>). However, several studies have indicated that anxiety may have a more pronounced effect on CRF than depression in the early stages of cancer, which may be attributed to the predominance of anxiety as the primary emotional response in this stage (<xref ref-type="bibr" rid="B30">30</xref>). It is believed that anxiety/depression may contribute to loss of appetite, decreased engagement in physical activities, muscle tension, or disrupted sleep, all of which are associated with the occurrence or increased levels of CRF. The precise mechanisms underlying the relationship between anxiety/depression and CRF are multifaceted and not completely understood; however, they may involve dysregulation of the HPA axis, alterations in neurotransmitter levels, and inflammatory responses (<xref ref-type="bibr" rid="B31">31</xref>).</p>
<p>In addition to anxiety and depression, there are many psychosocial risk factors of CRF, such as childhood stress, loneliness, and &#x201c;catastrophize&#x201d; of cancer. Conversely, CRF can also impact social, cognitive, and emotional functioning (<xref ref-type="bibr" rid="B4">4</xref>). The effects of CRF on social, cognitive, and emotional functioning is an integral component in various CRF scales. Moreover, recent research indicates that CRF, along with multiple cancer-related symptoms such as depression, anxiety, insomnia, poor concentration, and other cognitive impairments, is increasingly being reported as symptom clusters (<xref ref-type="bibr" rid="B32">32</xref>), which indicates that CRF and these symptoms may share similar mechanisms and interactions. The amelioration of one symptom is likely to improve others. Studying of associated risk factors contributes to early assessment, diagnosis, and management of CRF. Improving social, cognitive, and emotional functioning status of patients aids in reducing CRF, and avoiding the vicious cycle of &#x201c;fatigue-impairment in social/cognitive/emotional functioning-fatigue exacerbation.&#x201d;</p>
</sec>
<sec id="s4_2_2">
<label>4.2.2</label>
<title>Treatments</title>
<p>Over the past two decades, multiple randomized controlled trials have been conducted with CRF as a primary or secondary outcome measure. These studies have demonstrated diverse effective management strategies for CRF (<xref ref-type="bibr" rid="B4">4</xref>), especially non-pharmacological interventions such as exercise, yoga, and acupuncture.</p>
<p>Existing evidence suggests that exercise is the most effective therapeutic option for preventing and improving CRF and can be performed by patients with cancer of any stage (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The exercise guidelines (<xref ref-type="bibr" rid="B11">11</xref>) for cancer survivors recommend that engaging in moderately intense aerobic exercise (three times per week) for at least 12 weeks can significantly reduce CRF. A meta-analysis (<xref ref-type="bibr" rid="B12">12</xref>) of 245 studies revealed that among all types of exercise, relaxation exercises may be preferable for patients with CRF during cancer treatment. However, another study (<xref ref-type="bibr" rid="B33">33</xref>) concluded that a combination of aerobic and resistance exercises yields the most improvements in CRF, either during or after cancer treatment. In addition, it has been reported that aerobic exercise for improving CRF is more beneficial for patients with solid tumors than for those with hematological malignancies (<xref ref-type="bibr" rid="B34">34</xref>). It is important to consider variations in the type, duration, and intensity of exercise for different populations, such as patients with cancer who have bone metastases, anemia, or fever (<xref ref-type="bibr" rid="B1">1</xref>). Further research is warranted to provide evidence of the benefits of exercise in different populations of patients with CRF.</p>
<p>Yoga, a type of mind-body exercise, is widely performed to relieve cancer-related symptoms, particularly fatigue. Current guidelines recommend performing yoga to reduce CRF during and after cancer treatment (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B15">15</xref>). A Cochrane review (<xref ref-type="bibr" rid="B35">35</xref>) of 24 studies provided moderate-quality evidence that yoga improves CRF in patients with breast cancer compared with psychosocial/educational interventions. A meta-analysis (<xref ref-type="bibr" rid="B36">36</xref>) of 2,183 patients with breast cancer showed that an eight-week yoga regimen significantly mitigated the physical fatigue of the patients but had little effects on cognitive/mental fatigue. Yoga can regulate the dysregulation of the HPA axis, decrease plasma cortisol levels, and increase the release of endogenous dopamine and &#x3b3;-aminobutyric acid levels (<xref ref-type="bibr" rid="B37">37</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>). Some studies have been conducted to investigate the potential mechanisms underlying the improvement effect of yoga on CRF (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>), which may involve the modulation of the inflammatory processes, such as regulating the levels of inflammatory cytokines (e.g., IL-1&#x3b2;, IL-10), or the NF-&#x3ba;B pathway. Moreover, yoga may enhance glucocorticoid signal transduction and reduce sympathetic nervous system signaling through &#x3b2;-adrenergic receptors to influence inflammatory processes.</p>
<p>The American Society of Oncology and NCCN guidelines recommend acupuncture, an essential component of traditional Chinese medicine (TCM), for attenuating CRF in patients after cancer treatment (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B13">13</xref>). A meta-analysis (<xref ref-type="bibr" rid="B42">42</xref>) of 1,084 patients with breast cancer revealed that acupuncture can significantly reduce CRF compared with sham acupuncture or usual care. A minimum of six acupuncture sessions (e.g., weekly for 6 weeks, three times per week for 3 weeks), each lasting at least 20 minutes, has significant effects on CRF (<xref ref-type="bibr" rid="B43">43</xref>). Two studies (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>) demonstrated that acupuncture can inhibit neuroinflammation and gut inflammation by regulating the gut microbiota-gut-brain axis, decrease serum ghrelin, leptin, and insulin levels, and improve the dysfunction of the HPA axis to improve CRF. However, as further studies are still needed to verify the effects of acupuncture on CRF, the European Society for Medical Oncology panel has not yet reached a consensus on the recommendation of acupuncture for reducing CRF.</p>
<p>In addition to acupuncture, Chinese herbal medicines and Chinese medicine compound prescriptions have been shown to reduce CRF. Ginseng, a commonly used Chinese herbal medicine, tonifies the qi, nourishes the blood, and strengthens the spleen. A randomized trial (N07C2) (<xref ref-type="bibr" rid="B46">46</xref>) provided evidence to support the effects of American ginseng (Panax quinquefolius) (2000 mg/day) on CRF, and no discernible treatment-related toxicities are reported. Three systematic reviews (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>) have demonstrated that ginseng, including Asian, red, and American ginseng, can alleviate CRF. However, no clear criteria regarding the duration and dose of ginseng that should be administered to alleviate CRF have been established. Moreover, the effects of ginseng in reducing CRF may be influenced by various factors such as the type of ginseng, method of preparation, and ginsenoside content. In addition, huangqi (Radix Astragali), baizhu (Atractylodes macrocephala Koidz), and shanyao (Chinese yam) may regulate the levels of cytokines such as tumor necrosis factor-alpha (TNF-&#x3b1;) and interleukin-6 (IL-6), and inhibit oxidative stress to reduce CRF (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>Shengqi Fuzheng injection, which mainly consists of dangshen (Radix Codonopsis) and huangqi, improves mitochondrial dysfunction through the PI3K/Akt and AMPK signaling pathways, inhibits the levels of pro-inflammatory cytokines, and enhances immune function by downregulating multiple targets (PD-L1, TIM3, and FOXP3) to alleviate CRF (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). Moreover, the effects of the Buzhong Yiqi decoction, Jianpi Shengsui Gao, and Shiquan Dabu decoction have been validated in animal studies and clinical trials (<xref ref-type="bibr" rid="B54">54</xref>&#x2013;<xref ref-type="bibr" rid="B56">56</xref>). However, the evidence supporting these findings is of low quality; as such, TCM is not recommended for the treatment of CRF in any guideline. Therefore, further research on the effects of TCM on CRF is required.</p>
</sec>
<sec id="s4_2_3">
<label>4.2.3</label>
<title>Mechanisms</title>
<sec id="s4_2_3_1">
<label>4.2.3.1</label>
<title>Inflammation</title>
<p>The analysis conducted in this study indicated that inflammation is a hot topic in studies on the mechanisms of CRF (<xref ref-type="bibr" rid="B4">4</xref>). There are large variations in the symptoms experienced by both animals and humans after infections (<xref ref-type="bibr" rid="B57">57</xref>). These symptoms, including fatigue, significant changes in sleep patterns, and loss of appetite, are largely related to the effects of pro-inflammatory cytokines on the central nervous system. Persistent inflammation also plays an important role in CRF (<xref ref-type="bibr" rid="B58">58</xref>&#x2013;<xref ref-type="bibr" rid="B60">60</xref>), primarily because of the activation of a network of pro-inflammatory cytokines by anti-tumor therapies. A study (<xref ref-type="bibr" rid="B61">61</xref>) demonstrated that 65% of patients with acute myelogenous leukemia/myelodysplastic syndrome experience CRF before treatment, which is associated with IL-1RA, IL-6, and TNF-&#x3b1; levels. Chemotherapy and radiotherapy are commonly administered to treat cancer. Chemotherapy with platinum- or anthracycline-based agents may increase IL-8 and IL-6 levels, thereby leading to CRF (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). Increased serum levels of C-reactive protein (CRP) and IL-1RA are associated with increased CRF in patients undergoing radiotherapy (<xref ref-type="bibr" rid="B64">64</xref>). This correlation has also been observed in patients with advanced cancer (<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B66">66</xref>). Most breast cancer survivors with fatigue show upregulated expression of genes encoding pro-inflammatory cytokines compared with non-fatigued patients. In addition, cancer survivors with fatigue show increased expression of transcripts with response elements for NF-&#x3ba;B (<xref ref-type="bibr" rid="B67">67</xref>).</p>
<p>Other factors, such as psychological distress and insufficient sleep, can also affect inflammatory responses. Stress can activate peripheral inflammatory cytokines and related signaling pathways, such as the NF-&#x3ba;B signaling pathway, which are mediated by the activation of the sympathetic nervous system and the release of catecholamines (<xref ref-type="bibr" rid="B68">68</xref>&#x2013;<xref ref-type="bibr" rid="B70">70</xref>). A meta-analysis (<xref ref-type="bibr" rid="B71">71</xref>) showed that acute stress may lead to marked increase in circulating IL-1&#x3b2;, IL-6, IL-10, and TNF-&#x3b1; levels. In addition, insufficient sleep can lead to elevated CRP, IL-6, and TNF-&#x3b1; levels, which may be associated with reduced cortisol secretion and disrupted circadian rhythm (<xref ref-type="bibr" rid="B72">72</xref>&#x2013;<xref ref-type="bibr" rid="B74">74</xref>). Peripheral pro-inflammatory cytokines can access the brain through various pathways, activating microglia and astrocytes and contributing to neuroinflammation, which is a significant reason for the depression-like behaviors experienced by patients with CRF. Multiple inflammatory biomarkers, including CRP, IL-1RA, IL-6, sTNFR2, TNF-&#x3b1;, have been shown to be strongly associated with CRF. In addition, some of these biomarkers have been assessed as independent risk factors for CRF (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B75">75</xref>&#x2013;<xref ref-type="bibr" rid="B78">78</xref>). Moreover, some studies have confirmed that improvements in the levels of certain inflammatory markers can ameliorate CRF (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B79">79</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>).</p>
<p>Although the specific mechanism by which inflammation affects CRF remains elusive, it has been established that inflammation is intricately linked to neurotransmitter metabolism, HPA axis regulation, and skeletal muscle and mitochondrial dysfunction. Pro-inflammatory cytokines, such as IL-1&#x3b2;, IL-6, IFN-&#x3b1;, IFN-&#x3b3;, and TNF-&#x3b1;, can activate the indoleamine 2,3-dioxygenase (IDO) pathway, which increases the degradation of tryptophan into kynurenine through the kynurenine (KYN) pathway, leading to reduced serotonin levels (<xref ref-type="bibr" rid="B82">82</xref>). Serotonin, an essential neurotransmitter, influences depression and sleep; however, its effect on CRF remains controversial (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). The activation of the KYN pathway can also affect the functions of dopamine and norepinephrine. Kynurenic acid, generated from the degradation of kynurenine, can inhibit glutamatergic function, which may suppress the release of dopamine and result in CRF (<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B85">85</xref>). Methylphenidate, one of the few pharmacological therapies recommended for CRF in current clinical guidelines, acts by elevating dopamine levels (<xref ref-type="bibr" rid="B86">86</xref>).</p>
<p>Pro-inflammatory cytokines can influence the function of the HPA axis. The HPA axis regulates the generation of cytokines to exert anti-inflammatory effects through negative feedback control mechanisms (<xref ref-type="bibr" rid="B4">4</xref>). Cortisol, a glucocorticoid released by the HPA axis in response to factors such as inflammation, exhibits a clear circadian rhythm in healthy individuals. The diurnal cortisol rhythm appears flatter in cancer survivors with fatigue, indicating that patients with CRF experience disruptions in the circadian cortisol rhythm (<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Notably, the flattened cortisol secretion slope in cancer survivors with fatigue is attributed to elevated cortisol levels in the afternoon and evening. Furthermore, a study demonstrated that breast cancer survivors with fatigue exhibit diminished expression of glucocorticoid receptor anti-inflammatory transcription factors, indicating the presence of functional resistance to glucocorticoids, which may lead to the persistence of inflammatory responses (<xref ref-type="bibr" rid="B89">89</xref>).</p>
<p>Inflammation mediates mitochondrial dysfunction through various signaling pathways. For instance, IL-6 can activate STAT3 to disrupt homeostasis in skeletal muscles, whereas TNF-&#x3b1; can promote protein degradation in skeletal muscles by activating the NF-&#x3ba;B signaling pathway (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>). Studies have shown that inflammation increases the mitochondrial localization of NLRP3 and enhances the production of mitochondrial reactive oxygen species (ROS) (<xref ref-type="bibr" rid="B92">92</xref>). Dysfunctional mitochondria release excessive ROS and diminish adenosine triphosphate generation (<xref ref-type="bibr" rid="B93">93</xref>). Long-term elevation of the levels of ROS induces DNA damage, protein oxidation, and cellular apoptosis. Additionally, ROS can affect skeletal muscle function by interfering with the Akt/mTOR signaling pathway and augmenting protein hydrolysis (<xref ref-type="bibr" rid="B94">94</xref>). Mitochondrial and skeletal muscle dysfunction are important factors that influence CRF.</p>
</sec>
<sec id="s4_2_3_2">
<label>4.2.3.2</label>
<title>Hypoxia</title>
<p>Metabolic activities in immune cells change after inflammatory stimulation, such as increased oxygen consumption by activated neutrophils and elevation of glycolytic rates by activated macrophages and lymphocytes, leading to hypoxia (<xref ref-type="bibr" rid="B95">95</xref>). Studies show that mitochondrial dysfunction can exacerbate hypoxia within the tumor microenvironment. Under anoxic conditions, the hypoxia-inducible factor (HIF) is activated and serves as the dominant regulator of oxygen homeostasis (<xref ref-type="bibr" rid="B96">96</xref>). The HIF-&#x3b1; and HIF-&#x3b2; subunits induce transcription of multiple genes, such as NF-&#x3ba;B and toll-like receptors, promote the release of chemokines and cytokines, and stimulate the activation and recruitment of phagocytes and leukocytes to regulate the function of immune cells (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B98">98</xref>). HIF-1 also has the capacity to upregulate the expression of NADPH oxidase, augmenting the generation of ROS within the cytoplasm to promote oxidative stress (<xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>). In turn, ROS can enhance the stability of HIF-1 and facilitate the activation of both HIF-1 and NF-&#x3ba;B. Jianpi Shengsui Gao, a kind of TCM, enhances antioxidant stress via the HIF-1 pathway to mitigate CRF (<xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>Hypoxia-induced oxidative damage alters mitochondrial morphology, metabolism, and respiration (<xref ref-type="bibr" rid="B101">101</xref>). Mitochondrial autophagy is an adaptive metabolic response and a crucial mechanism for eliminating oxidatively damaged mitochondria, which contributes to the maintenance of energy metabolism. HIF induces mitochondrial autophagy by modulating the expression of BNIP3/Beclin-1 (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>). PHD2 is a key enzyme involved in the regulation of HIF-1&#x3b1; stability. A study showed that acteoside from Cistanche tubulosa can promote mitochondrial autophagy by suppressing PHD2 to reduce CRF (<xref ref-type="bibr" rid="B104">104</xref>). Existing evidence indicates that the HIF pathway may serve as a pivotal target in the treatment of chronic inflammation, which also plays a role in immune regulation and antitumor activity (<xref ref-type="bibr" rid="B105">105</xref>&#x2013;<xref ref-type="bibr" rid="B108">108</xref>). Although research on the HIF pathway is still in its nascent stage, particularly in the context of CRF, the HIF pathway represents an exciting therapeutic target that warrants further investigation.</p>
<p>Whether CRF originated in the central or peripheral remains controversial. Previous studies examining electroencephalogram (EEG), fatigue-related muscle contractile properties, and electromyogram (EMG) supported the findings of central origin of CRF (<xref ref-type="bibr" rid="B109">109</xref>&#x2013;<xref ref-type="bibr" rid="B113">113</xref>). Another study quantifying EEG-EMG coherence indicated significant and robust weakening of corticomuscular signal coupling in CRF patients, which may be caused by central and peripheral neuropathies (<xref ref-type="bibr" rid="B114">114</xref>). Although the mechanism of neuroelectric activity of CRF is still unclear, improving neuromuscular transmission may also be an important method for CRF treatment. Certainly, more research is needed. On the other hand, whether CRF is of central or peripheral origin, inflammation may play a central role. Pro-inflammatory cytokines can promote neuroinflammation through multiple pathways, affecting central nervous system function and neurotransmitter metabolism. Inflammation is also related to skeletal muscle mitochondrial function. The joint action of inflammation and skeletal muscle mitochondria can lead to hypoxia and abnormal oxidative stress response, which in turn aggravates inflammation and skeletal muscle mitochondrial dysfunction. This study indicates the importance of inflammation in the CRF field, and hypoxia is a possible research direction in the future. Targeting related pathways may be a new method to reduce CRF.</p>
</sec>
</sec>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Emerging areas on CRF</title>
<p>The results of this analysis indicate that recent research on the risk factors for CRF has predominantly been focused on insomnia, anxiety, and depression. Anemia remains a risk factor for CRF, and erythropoietin is recommended for patients with CRF and concomitant anemia (<xref ref-type="bibr" rid="B1">1</xref>). The main potential mechanisms by which insomnia, anxiety, and depression cause CRF include inflammation, HPA axis dysregulation, neurotransmitter alterations, and disturbances in circadian rhythms. Analysis of the keywords with the strongest citation bursts highlights inflammation as current hotspot in research on the mechanisms underlying the development of CRF. Inflammation is closely associated with HPA axis dysfunction, alterations in neurotransmitters, disruptions in circadian rhythms, and skeletal muscle and mitochondrial dysfunction, all of which collectively exert a synergistic effect on the onset and progression of CRF. Several studies have indicated that modulating the levels of pro-inflammatory cytokines, such as IL-1RA, IL-6, and TNF-&#x3b1;, to ameliorate systemic and neural inflammation can effectively alleviate CRF (<xref ref-type="bibr" rid="B79">79</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>).</p>
<p>Cluster analysis of keywords indicated that hypoxia is a potential mechanism underlying the development of CRF, possibly representing an emerging topic for future studies in the field of CRF research. HIF-related pathways are activated in hypoxic conditions, which can modulate the functions of immune cells, release of inflammatory cytokines, oxidative stress status, and mitochondrial function. Targeting HIF-related pathways has been proven to be a possible therapeutic strategy for various chronic inflammatory and neurodegenerative diseases (<xref ref-type="bibr" rid="B115">115</xref>) and may potentially aid the improvement of CRF (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B104">104</xref>). However, further substantiation through more evidence is warranted to determine whether targeting HIF-related pathways can ameliorate CRF.</p>
<p>The findings of this study highlight the current research hotspots regarding the risk factors, treatments, and mechanisms of CRF, and provide novel insights into future therapeutic directions for CRF. Notably, the results of this study indicated that hypoxia, which is closely associated with inflammation, is one of the less explored mechanisms underlying the development of CRF. Further studies are needed to clarify whether hypoxia-associated pathways can be crucial targets in the treatment of CRF.</p>
<p>Treatment strategies for CRF have been evaluated in previous studies. According to existing guidelines, exercise is the most effective intervention for improving CRF. However, there is no consensus on the optimal type, frequency, and intensity of exercise suitable for various types and stages of cancer. Future in-depth studies on this topic are needed to aid clinicians in designing optimal treatment strategies for patients with CRF. Acupuncture has demonstrated significant efficacy in ameliorating cancer-related symptoms. However, future extensive, large-scale, clinical studies are needed to verify its potential in improving CRF.</p>
<p>This study has some limitations. First, we only retrieved English literature related to CRF from the SSCI and SCI-Expanded databases through the WoSCC. Unpublished articles and articles published in other languages were not included. Second, the literature search was limited to articles with &#x201c;cancer-related fatigue&#x201d; in their titles, abstracts, or keywords, potentially leading to the data being insufficiently comprehensive.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>This study is the first and visualization analyses of cancer-related fatigue research published worldwide over the past two decades. The collaboration among researchers, institutions, and countries is limited. In addition, the results provides a comprehensive overview for global researchers, clinical practitioners, and decision-makers regarding the research focal points on risk factors, treatments, and potential mechanisms of cancer-related fatigue. Notably, the research findings indicate that hypoxia is a potential mechanism of cancer-related fatigue that merits further investigation. The HIF-related pathways could potentially serve as novel targets for the treatment of cancer-related fatigue.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>PL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. QW: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x2013; original draft. LF: Conceptualization, Supervision, Writing &#x2013; review &amp; editing. ZD: Conceptualization, Funding acquisition, Supervision, Writing &#x2013; review &amp; editing. WF: Conceptualization, Methodology, Writing&#xa0;&#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by the Capital Health Research and Development of Special (Grant Number 2020-2-4026), the Traditional Chinese medicine &#x201c;double-chain integration&#x201d; young and middle-aged scientific research and innovation team (Grant Number 2022-SLRH-LG-005), the Qin Chuangyuan &#x201c;scientist + engineer&#x201d; team construction of Shaanxi Province (Grant Number 2022KXJ-019), and the Key research and development projects of Shanxi Province (Grant Number 2023ZDLSF-56). The funders had no role in the design and performance of the study; extraction, synthesis, and analysis of the data; preparation, editing, and approval of the manuscript; and the decision to publicize the manuscript.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We appreciate Home-for-Researchers and Editage for language editing for us.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2024.1338325/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2024.1338325/full#supplementary-material</ext-link>.</p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>NCCN Clinical Practice Guidelines in Oncology</collab>
</person-group>. <article-title>Cancer-related fatigue version 2.2023</article-title> (<year>2023</year>). Available online at: <uri xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=3&amp;id=1424">https://www.nccn.org/guidelines/guidelines-detail?category=3&amp;id=1424</uri> (Accessed <access-date>January 30, 2023</access-date>).</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>B</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence and risk factors of cancer-related fatigue: A systematic review and meta-analysis</article-title>. <source>Int J Nurs Stud</source>. (<year>2020</year>) <volume>111</volume>:<fpage>103707</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijnurstu.2020.103707</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horneber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fischer</surname> <given-names>I</given-names>
</name>
<name>
<surname>Dimeo</surname> <given-names>F</given-names>
</name>
<name>
<surname>R&#xfc;ffer</surname> <given-names>JU</given-names>
</name>
<name>
<surname>Weis</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment</article-title>. <source>Dtsch Arztebl Int</source>. (<year>2012</year>) <volume>109</volume>:<page-range>161&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3238/arztebl.2012.0161</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue&#x2013;mechanisms, risk factors, and treatments</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2014</year>) <volume>11</volume>:<fpage>597</fpage>&#x2013;<lpage>609</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrclinonc.2014.127</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Durairajanayagam</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tatagari</surname> <given-names>S</given-names>
</name>
<name>
<surname>Esteves</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Harlev</surname> <given-names>A</given-names>
</name>
<name>
<surname>Henkel</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Bibliometrics: tracking research impact by selecting the appropriate metrics</article-title>. <source>Asian J Androl</source>. (<year>2016</year>) <volume>18</volume>:<fpage>296</fpage>&#x2013;<lpage>309</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/1008-682X.171582</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature</article-title>. <source>J Am Soc Inf Sci Technol</source>. (<year>2006</year>) <volume>57</volume>:<page-range>359&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/asi.20317</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Page</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Bossuyt</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Boutron</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hoffmann</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Mulrow</surname> <given-names>CD</given-names>
</name>
<etal/>
</person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n71</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aria</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cuccurullo</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>bibliometrix: An R-tool for comprehensive science mapping analysis</article-title>. <source>J Informetrics</source>. (<year>2017</year>) <volume>11</volume>:<page-range>959&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.joi.2017.08.007</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mustian</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Alfano</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Heckler</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kleckner</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Kleckner</surname> <given-names>IR</given-names>
</name>
<name>
<surname>Leach</surname> <given-names>CR</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis</article-title>. <source>JAMA Oncol</source>. (<year>2017</year>) <volume>3</volume>:<page-range>961&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6914</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Mooney</surname> <given-names>K</given-names>
</name>
<name>
<surname>Alvarez-Perez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Breitbart</surname> <given-names>WS</given-names>
</name>
<name>
<surname>Carpenter</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Cella</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer-related fatigue, version 2.2015</article-title>. <source>J Natl Compr Canc Netw</source>. (<year>2015</year>) <volume>13</volume>:<page-range>1012&#x2013;39</page-range>. doi: <pub-id pub-id-type="doi">10.6004/jnccn.2015.0122</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Winters-Stone</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Wiskemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>May</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Schwartz</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Courneya</surname> <given-names>KS</given-names>
</name>
<etal/>
</person-group>. <article-title>Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable</article-title>. <source>Med Sci Sports Exerc</source>. (<year>2019</year>) <volume>51</volume>:<page-range>2375&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1249/MSS.0000000000002116</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilfiker</surname> <given-names>R</given-names>
</name>
<name>
<surname>Meichtry</surname> <given-names>A</given-names>
</name>
<name>
<surname>Eicher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nilsson Balfe</surname> <given-names>L</given-names>
</name>
<name>
<surname>Knols</surname> <given-names>RH</given-names>
</name>
<name>
<surname>Verra</surname> <given-names>ML</given-names>
</name>
<etal/>
</person-group>. <article-title>Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis</article-title>. <source>Br J Sports Med</source>. (<year>2018</year>) <volume>52</volume>:<page-range>651&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bjsports-2016-096422</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Bak</surname> <given-names>K</given-names>
</name>
<name>
<surname>Berger</surname> <given-names>A</given-names>
</name>
<name>
<surname>Breitbart</surname> <given-names>W</given-names>
</name>
<name>
<surname>Escalante</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Ganz</surname> <given-names>PA</given-names>
</name>
<etal/>
</person-group>. <article-title>Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation</article-title>. <source>J Clin Oncol</source>. (<year>2014</year>) <volume>32</volume>:<page-range>1840&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2013.53.4495</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrahams</surname> <given-names>HJG</given-names>
</name>
<name>
<surname>Gielissen</surname> <given-names>MFM</given-names>
</name>
<name>
<surname>Schmits</surname> <given-names>IC</given-names>
</name>
<name>
<surname>Verhagen</surname> <given-names>CAHHVM</given-names>
</name>
<name>
<surname>Rovers</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Knoop</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors</article-title>. <source> Ann Oncol</source>. (<year>2016</year>) <volume>27</volume>:<page-range>965&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdw099</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bhargava</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fatigoni</surname> <given-names>S</given-names>
</name>
<name>
<surname>Guglielmo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Horneber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Roila</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment</article-title>. <source>Ann Oncol</source>. (<year>2020</year>) <volume>31</volume>:<page-range>713&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.016</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ryan</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Figueroa-Moseley</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Jean-Pierre</surname> <given-names>P</given-names>
</name>
<name>
<surname>Morrow</surname> <given-names>GR</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue: the scale of the problem</article-title>. <source>Oncologist</source>. (<year>2007</year>) <volume>12</volume>:<page-range>4&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1634/theoncologist.12-S1-4</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saligan</surname> <given-names>LN</given-names>
</name>
<name>
<surname>Olson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Filler</surname> <given-names>K</given-names>
</name>
<name>
<surname>Larkin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cramp</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yennurajalingam</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The biology of cancer-related fatigue: a review of the literature</article-title>. <source>Support Care Cancer</source>. (<year>2015</year>) <volume>23</volume>:<page-range>2461&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00520-015-2763-0</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curt</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Breitbart</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cella</surname> <given-names>D</given-names>
</name>
<name>
<surname>Groopman</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Horning</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Itri</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition</article-title>. <source>Oncologist</source>. (<year>2000</year>) <volume>5</volume>:<page-range>353&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1634/theoncologist.5-5-353</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holzner</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kemmler</surname> <given-names>G</given-names>
</name>
<name>
<surname>Greil</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kopp</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zeimet</surname> <given-names>A</given-names>
</name>
<name>
<surname>Raderer</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The impact of hemoglobin levels on fatigue and quality of life in cancer patients</article-title>. <source>Ann Oncol</source>. (<year>2002</year>) <volume>13</volume>:<page-range>965&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdf122</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DSilva</surname> <given-names>F</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>P</given-names>
</name>
<name>
<surname>Javeth</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Determinants of cancer-related fatigue among cancer patients: A systematic review</article-title>. <source>J Palliat Care</source>. (<year>2022</year>) <volume>2022</volume>:<fpage>8258597221131133</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/08258597221131133</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Ke</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Risk factors for cancer-related fatigue in patients with colorectal cancer: a systematic review and meta-analysis</article-title>. <source>Support Care Cancer</source>. (<year>2022</year>) <volume>30</volume>:<page-range>10311&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00520-022-07432-5</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasc&#xf3;n</surname> <given-names>P</given-names>
</name>
<name>
<surname>Arranz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bargay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ramos</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma</article-title>. <source>Support Care Cancer</source>. (<year>2018</year>) <volume>26</volume>:<page-range>1253&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00520-017-3948-5</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minton</surname> <given-names>O</given-names>
</name>
<name>
<surname>Richardson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sharpe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hotopf</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stone</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue</article-title>. <source>J Natl Cancer Inst</source>. (<year>2008</year>) <volume>100</volume>:<page-range>1155&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jnci/djn250</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Acupuncture for cancer-related insomnia: A systematic review and meta-analysis</article-title>. <source>Phytomedicine</source>. (<year>2022</year>) <volume>102</volume>:<fpage>154160</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2022.154160</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zee</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Ancoli-Israel</surname> <given-names>S</given-names>
</name>
<collab>Workshop Participants</collab>
</person-group>. <article-title>Does effective management of sleep disorders reduce cancer-related fatigue</article-title>? <source>Drugs</source>. (<year>2009</year>) <volume>69</volume>:<fpage>29</fpage>&#x2013;<lpage>41</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2165/11531140-000000000-00000</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz-Casado</surname> <given-names>A</given-names>
</name>
<name>
<surname>&#xc1;lvarez-Bustos</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Pedro</surname> <given-names>CG</given-names>
</name>
<name>
<surname>M&#xe9;ndez-Otero</surname> <given-names>M</given-names>
</name>
<name>
<surname>Romero-El&#xed;as</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue in breast cancer survivors: A review</article-title>. <source>Clin Breast Cancer</source>. (<year>2021</year>) <volume>21</volume>:<fpage>10</fpage>&#x2013;<lpage>25</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.clbc.2020.07.011</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Suleman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hyde</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hodgkiss</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Depression and anxiety in patients with cancer</article-title>. <source>BMJ</source>. (<year>2018</year>) <volume>361</volume>:<fpage>k1415</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.k1415</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lobefaro</surname> <given-names>R</given-names>
</name>
<name>
<surname>Rota</surname> <given-names>S</given-names>
</name>
<name>
<surname>Porcu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brunelli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Alfieri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zito</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors</article-title>. <source>ESMO Open</source>. (<year>2022</year>) <volume>7</volume>:<fpage>100457</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100457</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Kroenke</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue and its associations with depression and anxiety: a systematic review</article-title>. <source>Psychosomatics</source>. (<year>2009</year>) <volume>50</volume>:<page-range>440&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0033-3182(09)70835-7</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname> <given-names>RT</given-names>
</name>
<name>
<surname>Kwan</surname> <given-names>TT</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>IK</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>PH</given-names>
</name>
<name>
<surname>Yip</surname> <given-names>PS</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of fatigue with perceived stress in chinese women with early stage breast cancer awaiting adjuvant radiotherapy</article-title>. <source>Stress Health</source>. (<year>2015</year>) <volume>31</volume>:<page-range>214&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/smi.2548</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bortolato</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hyphantis</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Valpione</surname> <given-names>S</given-names>
</name>
<name>
<surname>Perini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Maes</surname> <given-names>M</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Depression in cancer: The many biobehavioral pathways driving tumor progression</article-title>. <source>Cancer Treat Rev</source>. (<year>2017</year>) <volume>52</volume>:<fpage>58</fpage>&#x2013;<lpage>70</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctrv.2016.11.004</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roscoe</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Kaufman</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Matteson-Rusby</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Palesh</surname> <given-names>OG</given-names>
</name>
<name>
<surname>Ryan</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Kohli</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer-related fatigue and sleep disorders</article-title>. <source>Oncologist</source>. (<year>2007</year>) <volume>Suppl 1</volume>:<fpage>35</fpage>&#x2013;<lpage>42</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1634/theoncologist.12-S1-35</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname> <given-names>B</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Which exercise approaches work for relieving cancer-related fatigue? A network meta-analysis</article-title>. <source>J Orthop Sports Phys Ther</source>. (<year>2023</year>) <volume>0</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.2519/jospt.2023.11251</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramp</surname> <given-names>F</given-names>
</name>
<name>
<surname>Byron-Daniel</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Exercise for the management of cancer-related fatigue in adults</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2012</year>) <volume>11</volume>:<fpage>CD006145</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD006145.pub3</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lauche</surname> <given-names>R</given-names>
</name>
<name>
<surname>Klose</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lange</surname> <given-names>S</given-names>
</name>
<name>
<surname>Langhorst</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dobos</surname> <given-names>GJ</given-names>
</name>
</person-group>. <article-title>Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2017</year>) <volume>1</volume>:<fpage>CD010802</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/14651858.CD010802.pub2</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jing</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis</article-title>. <source>Breast Cancer Res Treat</source>. (<year>2019</year>) <volume>177</volume>:<fpage>5</fpage>&#x2013;<lpage>16</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10549-019-05278-w</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Streeter</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Gerbarg</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Saper</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Ciraulo</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>RP</given-names>
</name>
</person-group>. <article-title>Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder</article-title>. <source>Med Hypotheses</source>. (<year>2012</year>) <volume>78</volume>:<page-range>571&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mehy.2012.01.021</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banasik</surname> <given-names>J</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>H</given-names>
</name>
<name>
<surname>Haberman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Blank</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Bendel</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors</article-title>. <source>J Am Acad Nurse Pract</source>. (<year>2011</year>) <volume>23</volume>:<page-range>135&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1745-7599.2010.00573.x</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Streeter</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Whitfield</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Owen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rein</surname> <given-names>T</given-names>
</name>
<name>
<surname>Karri</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Yakhkind</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS study</article-title>. <source>J Altern Complement Med</source>. (<year>2010</year>) <volume>16</volume>:<page-range>1145&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/acm.2010.0007</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Greendale</surname> <given-names>G</given-names>
</name>
<name>
<surname>Crosswell</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Garet</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sternlieb</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ganz</surname> <given-names>PA</given-names>
</name>
<etal/>
</person-group>. <article-title>Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial</article-title>. <source>Psychoneuroendocrinology</source>. (<year>2014</year>) <volume>43</volume>:<page-range>20&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.01.019</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yadav</surname> <given-names>V</given-names>
</name>
<name>
<surname>Shyam</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>SK</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term yogic intervention decreases serum interleukins IL-10 and IL-1&#x3b2; and improves cancer-related fatigue and functional scale during radiotherapy/chemotherapy in breast cancer patients: a randomized control study</article-title>. <source>Support Care Cancer</source>. (<year>2022</year>) <volume>31</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-022-07487-4</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname> <given-names>TY</given-names>
</name>
<name>
<surname>Ang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jun</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Alraek</surname> <given-names>T</given-names>
</name>
<name>
<surname>Birch</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Acupuncture for managing cancer-related fatigue in breast cancer patients: A systematic review and meta-analysis</article-title>. <source>Cancers (Basel)</source>. (<year>2022</year>) <volume>14</volume>:<fpage>4419</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers14184419</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Effects of acupuncture on cancer-related fatigue: a meta-analysis</article-title>. <source>Support Care Cancer</source>. (<year>2018</year>) <volume>26</volume>:<page-range>415&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00520-017-3955-6</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Su</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Acupuncture ameliorates breast cancer-related fatigue by regulating the gut microbiota-gut-brain axis</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>921119</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.921119</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Effects of mind-regulation acupuncture therapy on serum ghrelin, gastric inhibitory polypeptide, leptin, and insulin levels in breast cancer survivors with cancer-related fatigue: A randomized controlled trial</article-title>. <source>Int J Gen Med</source>. (<year>2023</year>) <volume>16</volume>:<page-range>1017&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/IJGM.S405977</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Dakhil</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Linquist</surname> <given-names>B</given-names>
</name>
<name>
<surname>Sloan</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Nichols</surname> <given-names>CR</given-names>
</name>
<etal/>
</person-group>. <article-title>Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2</article-title>. <source>J Natl Cancer Inst</source>. (<year>2013</year>) <volume>105</volume>:<page-range>1230&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jnci/djt181</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najafi</surname> <given-names>TF</given-names>
</name>
<name>
<surname>Bahri</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tohidinik</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Feyz</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bloki</surname> <given-names>F</given-names>
</name>
<name>
<surname>Savarkar</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of cancer-related fatigue with ginseng: A systematic review and meta-analysis</article-title>. <source>J Herbal Med</source>. (<year>2021</year>) <volume>28</volume>:<fpage>100440</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.hermed.2021.100440</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname> <given-names>WT</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>TW</given-names>
</name>
</person-group>. <article-title>Effects of ginseng on cancer-related fatigue: A systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Cancer Nurs</source>. (<year>2023</year>) <volume>46</volume>:<page-range>120&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/NCC.0000000000001068</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadeghian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rahmani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zendehdel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hosseini</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Zare Javid</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Ginseng and cancer-related fatigue: A systematic review of clinical trials</article-title>. <source>Nutr Cancer</source>. (<year>2021</year>) <volume>73</volume>:<page-range>1270&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/01635581.2020.1795691</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Database mining and animal experiment-based validation of the efficacy and mechanism of Radix Astragali (Huangqi) and Rhizoma Atractylodis Macrocephalae (Baizhu) as core drugs of Traditional Chinese medicine in cancer-related fatigue</article-title>. <source>J Ethnopharmacol</source>. (<year>2022</year>) <volume>285</volume>:<fpage>114892</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jep.2021.114892</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of the polysaccharides extracted from Chinese yam (Dioscorea opposita Thunb.) on cancer-related fatigue in mice</article-title>. <source>Food Funct</source>. (<year>2021</year>) <volume>12</volume>:<page-range>10602&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/D1FO00375E</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Network pharmacology/metabolomics-based validation of AMPK and PI3K/AKT signaling pathway as a central role of shengqi fuzheng injection regulation of mitochondrial dysfunction in cancer-related fatigue</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2021</year>) <volume>2021</volume>:<fpage>5556212</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/5556212</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>ShenQi FuZheng Injection ameliorates fatigue-like behavior in mouse models of cancer-related fatigue</article-title>. <source>BioMed Pharmacother</source>. (<year>2019</year>) <volume>111</volume>:<page-range>1376&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2019.01.042</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>The clinical application and pharmacological mechanism of Bu-Zhong-Yi-Qi decoction for treating cancer-related fatigue: An overview</article-title>. <source>BioMed Pharmacother</source>. (<year>2022</year>) <volume>156</volume>:<fpage>113969</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2022.113969</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Jian Pi Sheng Sui Gao (JPSSG) alleviation of skeletal myoblast cell apoptosis, oxidative stress, and mitochondrial dysfunction to improve cancer-related fatigue in an AMPK-SIRT1- and HIF-1-dependent manner</article-title>. <source>Ann Transl Med</source>. (<year>2023</year>) <volume>11</volume>:<fpage>156</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Eo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>Traditional herbal medicine, sipjeondaebo-tang, for cancer-related fatigue: A randomized, placebo-controlled, preliminary study</article-title>. <source>Integr Cancer Ther</source>. (<year>2021</year>) <volume>20</volume>:<fpage>15347354211040830</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/15347354211040830</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelley</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Bluth&#xe9;</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Dantzer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>WH</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>RW</given-names>
</name>
<etal/>
</person-group>. <article-title>Cytokine-induced sickness behavior</article-title>. <source>Brain Behav Immun</source>. (<year>2003</year>) <volume>17 Suppl 1</volume>:<page-range>S112&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0889-1591(02)00077-6</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Higgins</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Brady</surname> <given-names>B</given-names>
</name>
<name>
<surname>O&#x2019;Connor</surname> <given-names>B</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>D</given-names>
</name>
<name>
<surname>Reilly</surname> <given-names>RB</given-names>
</name>
</person-group>. <article-title>The pathophysiology of cancer-related fatigue: current controversies</article-title>. <source>Support Care Cancer</source>. (<year>2018</year>) <volume>26</volume>:<page-range>3353&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00520-018-4318-7</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ai</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>A narrative review of cancer-related fatigue (CRF) and its possible pathogenesis</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>8</volume>:<fpage>738</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells8070738</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue: links with inflammation in cancer patients and survivors</article-title>. <source>Brain Behav Immun</source>. (<year>2007</year>) <volume>21</volume>:<page-range>863&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2007.03.013</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyers</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Albitar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Estey</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome</article-title>. <source>Cancer</source>. (<year>2005</year>) <volume>104</volume>:<page-range>788&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.21234</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Platinum accumulation and cancer-related fatigue, correlation with IL-8, TNF-&#x3b1; and hemocytes</article-title>. <source>Front Pharmacol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>658792</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2021.658792</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Rissling</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fiorentino</surname> <given-names>L</given-names>
</name>
<name>
<surname>Natarajan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dimsdale</surname> <given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy</article-title>. <source>Brain Behav Immun</source>. (<year>2012</year>) <volume>26</volume>:<page-range>706&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2012.02.001</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Ganz</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Belin</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Sepah</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer</article-title>. <source>Clin Cancer Res</source>. (<year>2009</year>) <volume>15</volume>:<page-range>5534&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2584</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Raaf</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Sleijfer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lamers</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Jager</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gratama</surname> <given-names>JW</given-names>
</name>
<name>
<surname>van der Rijt</surname> <given-names>CC</given-names>
</name>
</person-group>. <article-title>Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study</article-title>. <source>Cancer</source>. (<year>2012</year>) <volume>118</volume>:<page-range>6005&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.27613</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyes-Gibby</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Spitz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yennurajalingam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shete</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients</article-title>. <source>J Pain Symptom Manage</source>. (<year>2013</year>) <volume>46</volume>:<page-range>161&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2012.07.019</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Ganz</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Irwin</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Arevalo</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Cole</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>Fatigue and gene expression in human leukocytes: increased NF-&#x3ba;B and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue</article-title>. <source>Brain Behav Immun</source>. (<year>2011</year>) <volume>25</volume>:<page-range>147&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2010.09.010</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bierhaus</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wolf</surname> <given-names>J</given-names>
</name>
<name>
<surname>Andrassy</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rohleder</surname> <given-names>N</given-names>
</name>
<name>
<surname>Humpert</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Petrov</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>A mechanism converting psychosocial stress into mononuclear cell activation</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2003</year>) <volume>100</volume>:<page-range>1920&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0438019100</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pace</surname> <given-names>TW</given-names>
</name>
<name>
<surname>Mletzko</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Alagbe</surname> <given-names>O</given-names>
</name>
<name>
<surname>Musselman</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Nemeroff</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>AH</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress</article-title>. <source>Am J Psychiatry</source>. (<year>2006</year>) <volume>163</volume>:<page-range>1630&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1176/ajp.2006.163.9.1630</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Campisi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sharkey</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Kennedy</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Nickerson</surname> <given-names>M</given-names>
</name>
<name>
<surname>Greenwood</surname> <given-names>BN</given-names>
</name>
<etal/>
</person-group>. <article-title>Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines</article-title>. <source>Neuroscience</source>. (<year>2005</year>) <volume>135</volume>:<page-range>1295&#x2013;307</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.06.090</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsland</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lockwood</surname> <given-names>K</given-names>
</name>
<name>
<surname>John-Henderson</surname> <given-names>NA</given-names>
</name>
</person-group>. <article-title>The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis</article-title>. <source>Brain Behav Immun</source>. (<year>2017</year>) <volume>64</volume>:<page-range>208&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.011</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier-Ewert</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Ridker</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Rifai</surname> <given-names>N</given-names>
</name>
<name>
<surname>Regan</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Price</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Dinges</surname> <given-names>DF</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk</article-title>. <source>J Am Coll Cardiol</source>. (<year>2004</year>) <volume>43</volume>:<page-range>678&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2003.07.050</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vgontzas</surname> <given-names>AN</given-names>
</name>
<name>
<surname>Zoumakis</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bixler</surname> <given-names>EO</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Follett</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kales</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2004</year>) <volume>89</volume>:<page-range>2119&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jc.2003-031562</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Ancoli-Israel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bower</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Capuron</surname> <given-names>L</given-names>
</name>
<name>
<surname>Irwin</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer</article-title>. <source>J Clin Oncol</source>. (<year>2008</year>) <volume>26</volume>:<page-range>971&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2007.10.7805</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Felger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mister</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Torres</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors</article-title>. <source>Psychol Med</source>. (<year>2017</year>) <volume>47</volume>:<page-range>1733&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/S0033291717000150</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jaskulski</surname> <given-names>S</given-names>
</name>
<name>
<surname>Behrens</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>AY</given-names>
</name>
<name>
<surname>Obi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Tired of feeling tired - The role of circulating inflammatory biomarkers and long-term cancer related fatigue in breast cancer survivors</article-title>. <source>Breast</source>. (<year>2021</year>) <volume>56</volume>:<page-range>103&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.breast.2021.02.008</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>S</given-names>
</name>
<name>
<surname>Natarajan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Dimsdale</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review</article-title>. <source>Brain Behav Immun</source>. (<year>2007</year>) <volume>21</volume>:<page-range>413&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2006.11.004</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pertl</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Hevey</surname> <given-names>D</given-names>
</name>
<name>
<surname>Boyle</surname> <given-names>NT</given-names>
</name>
<name>
<surname>Hughes</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Collier</surname> <given-names>S</given-names>
</name>
<name>
<surname>O&#x2019;Dwyer</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy</article-title>. <source>Brain Behav Immun</source>. (<year>2013</year>) <volume>34</volume>:<page-range>108&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2013.07.177</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norden</surname> <given-names>DM</given-names>
</name>
<name>
<surname>McCarthy</surname> <given-names>DO</given-names>
</name>
<name>
<surname>Bicer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Devine</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Reiser</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Godbout</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice</article-title>. <source>Life Sci</source>. (<year>2015</year>) <volume>143</volume>:<fpage>65</fpage>&#x2013;<lpage>70</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lfs.2015.10.020</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inglis</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Kerns</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Kleckner</surname> <given-names>IR</given-names>
</name>
<name>
<surname>Kleckner</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Castillo</surname> <given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>Nutritional interventions for treating cancer-related fatigue: A qualitative review</article-title>. <source>Nutr Cancer</source>. (<year>2019</year>) <volume>71</volume>:<fpage>21</fpage>&#x2013;<lpage>40</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/01635581.2018.1513046</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Kuo</surname> <given-names>KT</given-names>
</name>
<name>
<surname>Bamodu</surname> <given-names>OA</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>YK</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>KY</given-names>
</name>
<etal/>
</person-group>. <article-title>Astragalus polysaccharide (PG2) Ameliorates Cancer Symptom Clusters, as well as Improves Quality of Life in Patients with Metastatic Disease, through Modulation of the Inflammatory Cascade</article-title>. <source>Cancers (Basel)</source>. (<year>2019</year>) <volume>11</volume>:<fpage>1054</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers11081054</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Stefanek</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>AH</given-names>
</name>
</person-group>. <article-title>Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue</article-title>. <source>Cancer</source>. (<year>2015</year>) <volume>121</volume>:<page-range>2129&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.29302</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Hickok</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Roscoe</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Raubertas</surname> <given-names>RF</given-names>
</name>
<name>
<surname>Andrews</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Flynn</surname> <given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program</article-title>. <source>J Clin Oncol</source>. (<year>2003</year>) <volume>21</volume>:<page-range>4635&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2003.04.070</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norden</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Devine</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bicer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jing</surname> <given-names>R</given-names>
</name>
<name>
<surname>Reiser</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Wold</surname> <given-names>LE</given-names>
</name>
<etal/>
</person-group>. <article-title>Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue</article-title>. <source>Physiol Behav</source>. (<year>2015</year>) <volume>140</volume>:<page-range>230&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.physbeh.2014.12.045</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raison</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Dantzer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kelley</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Lawson</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Woolwine</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Vogt</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression</article-title>. <source>Mol Psychiatry</source>. (<year>2010</year>) <volume>15</volume>:<fpage>393</fpage>&#x2013;<lpage>403</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/mp.2009.116</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname> <given-names>PC</given-names>
</name>
</person-group>. <article-title>Methylphenidate in the management of cancer-related fatigue</article-title>. <source>J Clin Oncol</source>. (<year>2013</year>) <volume>31</volume>:<page-range>2372&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/JCO.2013.50.0181</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Semik</surname> <given-names>J</given-names>
</name>
<name>
<surname>Habermann</surname> <given-names>N</given-names>
</name>
<name>
<surname>Wiskemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ulrich</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Steindorf</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients</article-title>. <source>Brain Behav Immun</source>. (<year>2016</year>) <volume>52</volume>:<fpage>98</fpage>&#x2013;<lpage>105</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2015.10.005</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuneo</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Schrepf</surname> <given-names>A</given-names>
</name>
<name>
<surname>Slavich</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Thaker</surname> <given-names>PH</given-names>
</name>
<name>
<surname>Goodheart</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bender</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer</article-title>. <source>Psychoneuroendocrinology</source>. (<year>2017</year>) <volume>84</volume>:<page-range>139&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.psyneuen.2017.06.019</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname> <given-names>GE</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sze</surname> <given-names>J</given-names>
</name>
<name>
<surname>Marin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Arevalo</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Doll</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling</article-title>. <source>Biol Psychiatry</source>. (<year>2008</year>) <volume>64</volume>:<page-range>266&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.03.017</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carson</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Hardee</surname> <given-names>JP</given-names>
</name>
<name>
<surname>VanderVeen</surname> <given-names>BN</given-names>
</name>
</person-group>. <article-title>The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting</article-title>. <source>Semin Cell Dev Biol</source>. (<year>2016</year>) <volume>54</volume>:<fpage>53</fpage>&#x2013;<lpage>67</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semcdb.2015.11.005</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>VanderVeen</surname> <given-names>BN</given-names>
</name>
<name>
<surname>Fix</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Carson</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Disrupted skeletal muscle mitochondrial dynamics, mitophagy, and biogenesis during cancer cachexia: A role for inflammation</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2017</year>) <volume>2017</volume>:<fpage>3292087</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2017/3292087</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eggelbusch</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Broeksma</surname> <given-names>BC</given-names>
</name>
<name>
<surname>V&#xe1;zquez-Cruz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soares</surname> <given-names>MN</given-names>
</name>
<name>
<surname>de Wit</surname> <given-names>GMJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle</article-title>. <source>J Cachexia Sarcopenia Muscle</source>. (<year>2022</year>) <volume>13</volume>:<page-range>3048&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcsm.13062</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLean</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Moylan</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Andrade</surname> <given-names>FH</given-names>
</name>
</person-group>. <article-title>Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes</article-title>. <source>Front Physiol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>503</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2014.00503</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyatt</surname> <given-names>HW</given-names>
</name>
<name>
<surname>Powers</surname> <given-names>SK</given-names>
</name>
</person-group>. <article-title>Mitochondrial dysfunction is a common denominator linking skeletal muscle wasting due to disease, aging, and prolonged inactivity</article-title>. <source>Antioxidants (Basel)</source>. (<year>2021</year>) <volume>10</volume>:<fpage>588</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antiox10040588</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Colgan</surname> <given-names>SP</given-names>
</name>
</person-group>. <article-title>Regulation of immunity and inflammation by hypoxia in immunological niches</article-title>. <source>Nat Rev Immunol</source>. (<year>2017</year>) <volume>17</volume>:<page-range>774&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2017.103</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaelin</surname> <given-names>WG</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Ratcliffe</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway</article-title>. <source>Mol Cell</source>. (<year>2008</year>) <volume>30</volume>:<fpage>393</fpage>&#x2013;<lpage>402</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molcel.2008.04.009</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eltzschig</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Carmeliet</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Hypoxia and inflammation</article-title>. <source>N Engl J Med</source>. (<year>2011</year>) <volume>364</volume>:<page-range>656&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra0910283</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlicke</surname> <given-names>J</given-names>
</name>
<name>
<surname>Frick</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Morote-Garcia</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Rosenberger</surname> <given-names>P</given-names>
</name>
<name>
<surname>Eltzschig</surname> <given-names>HK</given-names>
</name>
</person-group>. <article-title>Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia</article-title>. <source>PloS One</source>. (<year>2007</year>) <volume>2</volume>:<elocation-id>e1364</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0001364</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korbecki</surname> <given-names>J</given-names>
</name>
<name>
<surname>Simi&#x144;ska</surname> <given-names>D</given-names>
</name>
<name>
<surname>G&#x105;ssowska-Dobrowolska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Listos</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gutowska</surname> <given-names>I</given-names>
</name>
<name>
<surname>Chlubek</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-&#x3ba;B activation: A review of the molecular mechanisms</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>10701</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms221910701</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diebold</surname> <given-names>I</given-names>
</name>
<name>
<surname>Petry</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hess</surname> <given-names>J</given-names>
</name>
<name>
<surname>G&#xf6;rlach</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1</article-title>. <source>Mol Biol Cell</source>. (<year>2010</year>) <volume>21</volume>:<page-range>2087&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1091/mbc.e09-12-1003</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuhrmann</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Br&#xfc;ne</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Mitochondrial composition and function under the control of hypoxia</article-title>. <source>Redox Biol</source>. (<year>2017</year>) <volume>12</volume>:<page-range>208&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2017.02.012</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bosch-Marce</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shimoda</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Baek</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Wesley</surname> <given-names>JB</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia</article-title>. <source>J Biol Chem</source>. (<year>2008</year>) <volume>283</volume>:<page-range>10892&#x2013;903</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M800102200</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellot</surname> <given-names>G</given-names>
</name>
<name>
<surname>Garcia-Medina</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gounon</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chiche</surname> <given-names>J</given-names>
</name>
<name>
<surname>Roux</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pouyss&#xe9;gur</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains</article-title>. <source>Mol Cell Biol</source>. (<year>2009</year>) <volume>29</volume>:<page-range>2570&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/MCB.00166-09</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>F</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>A novel PHD2 inhibitor acteoside from Cistanche tubulosa induces skeletal muscle mitophagy to improve cancer-related fatigue</article-title>. <source>BioMed Pharmacother</source>. (<year>2022</year>) <volume>150</volume>:<fpage>113004</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2022.113004</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scholz</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>CT</given-names>
</name>
</person-group>. <article-title>Targeting the HIF pathway in inflammation and immunity</article-title>. <source>Curr Opin Pharmacol</source>. (<year>2013</year>) <volume>13</volume>:<page-range>646&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.coph.2013.04.009</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Holt-Martyn</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Schofield</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Ratcliffe</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Pharmacological targeting of the HIF hydroxylases&#x2013;A new field in medicine development</article-title>. <source>Mol Aspects Med</source>. (<year>2016</year>) <volume>47-48</volume>:<fpage>54</fpage>&#x2013;<lpage>75</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mam.2016.01.001</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyrakis</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Palazon</surname> <given-names>A</given-names>
</name>
<name>
<surname>Macias</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Phan</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Veli&#xe7;a</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate</article-title>. <source>Nature</source>. (<year>2016</year>) <volume>540</volume>:<page-range>236&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature20165</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jing</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>K</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of hypoxia in cancer therapy by regulating the tumor microenvironment</article-title>. <source>Mol Cancer</source>. (<year>2019</year>) <volume>18</volume>:<fpage>157</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-019-1089-9</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allexandre</surname> <given-names>D</given-names>
</name>
<name>
<surname>Seyidova-Khoshknabi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>VK</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>EEG correlates of central origin of cancer-related fatigue</article-title>. <source>Neural Plast</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>8812984</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/8812984</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kisiel-Sajewicz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Seyidova-Khoshknabi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wyant</surname> <given-names>A</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Lack of muscle contractile property changes at the time of perceived physical exhaustion suggests central mechanisms contributing to early motor task failure in patients with cancer-related fatigue</article-title>. <source>J Pain Symptom Manage</source>. (<year>2012</year>) <volume>44</volume>:<page-range>351&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2011.08.007</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kisiel-Sajewicz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Seyidova-Khoshknabi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Wyant</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>VK</given-names>
</name>
<etal/>
</person-group>. <article-title>Myoelectrical manifestation of fatigue less prominent in patients with cancer related fatigue</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e83636</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0083636</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yavuzsen</surname> <given-names>T</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>VK</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>D</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Kirkova</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer-related fatigue: central or peripheral</article-title>? <source>J Pain Symptom Manage</source>. (<year>2009</year>) <volume>38</volume>:<page-range>587&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2008.12.003</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname> <given-names>B</given-names>
</name>
<name>
<surname>Allexandre</surname> <given-names>D</given-names>
</name>
<name>
<surname>Rajagopalan</surname> <given-names>V</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>VK</given-names>
</name>
<etal/>
</person-group>. <article-title>Evidence of significant central fatigue in patients with cancer-related fatigue during repetitive elbow flexions till perceived exhaustion</article-title>. <source>PloS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e115370</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0115370</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>T</given-names>
</name>
<name>
<surname>Siemionow</surname> <given-names>V</given-names>
</name>
<name>
<surname>Ranganathan</surname> <given-names>VK</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>AF</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional corticomuscular signal coupling is weakened during voluntary motor action in cancer-related fatigue</article-title>. <source>Neural Plast</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>2490750</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/2490750</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burtscher</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mallet</surname> <given-names>RT</given-names>
</name>
<name>
<surname>Burtscher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Millet</surname> <given-names>GP</given-names>
</name>
</person-group>. <article-title>Hypoxia and brain aging: Neurodegeneration or neuroprotection</article-title>? <source>Ageing Res Rev</source>. (<year>2021</year>) <volume>68</volume>:<fpage>101343</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.arr.2021.101343</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>